

CORRECTION

Open Access



Correction to: Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study

Hidehiko Tanihara^{1*}, Takahiko Kakuda², Tetsuro Sano², Takashi Kanno² and Ryoji Gunji²

Correction to: BMC Ophthalmol 20, 275 (2020)
<https://doi.org/10.1186/s12886-020-01490-1>

Following publication of the original article [1] the authors have notified us of an error in the Fig. 6. The corrected Fig. 6 is presented below:

Author details

¹Kumamoto University Hospital, Japan 1-1-1 Honjo, Chuo-ku, Kumamoto, Japan. ²Post Marketing Surveillance Department, Kowa Co., Ltd., Tokyo, Japan.

Published online: 04 September 2020

Reference

1. Tanihara H, et al. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study. *BMC Ophthalmol.* 2020;20:275. <https://doi.org/10.1186/s12886-020-01490-1>.

The original article can be found online at <https://doi.org/10.1186/s12886-020-01490-1>.


* Correspondence: tanihara@pearl.ocn.ne.jp

¹Kumamoto University Hospital, Japan 1-1-1 Honjo, Chuo-ku, Kumamoto, Japan

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



IOP, mmHg	<15 mmHg	≥15 to <21 mmHg	≥21 to <30 mmHg	≥30 to <35 mmHg	≥35 mmHg
IOP at baseline ^a (n)	12.3 ± 1.8 (983)	17.3 ± 1.7 (1462)	23.9 ± 2.3 (739)	31.7 ± 1.5 (73)	41.2 ± 6.2 (66)
IOP at Month 3 ^a (n)	11.8 ± 2.8 (959)	15.2 ± 3.2 (1420)	18.9 ± 4.7 (674)	25.1 ± 7.8 (60)	24.8 ± 10.4 (45)
IOP at Month 12 ^a (n)	11.7 ± 2.8 (606)	15.1 ± 3.1 (863)	18.0 ± 4.6 (371)	21.8 ± 7.0 (29)	21.9 ± 10.5 (23)
IOP change from baseline ^b	-0.5 ± 0.1 (983)	-2.1 ± 0.1 (1462)	-5.2 ± 0.2 (739)	-7.6 ± 0.9 (73)	-16.9 ± 1.2 (66)
P value ^c	<0.001	<0.001	<0.001	<0.001	<0.001

Fig. 6 Intraocular pressure and change in intraocular pressure in all patients according to baseline intraocular pressure values. IOP intraocular pressure. ^a Mean ± standard deviation. ^b Least-squares mean ± standard error. ^c Mixed effects model for repeated measures, baseline vs entire post-administration period